WellGenx and WaiveDx announced on August 26 the merger of the two companies.
WellGenx, headquartered in San Antonio, Texas, delivers genetics-based solutions for anti-aging, wellness, longevity and behavioral health. In collaboration with the National Institutes of Health, National Human Genome Center and multiple academic centers, the company specializes in supplement and neuronutrient formulations, at-home testing and precision protocols driven by DNA and lab-based data.
WaiveDx is an AI-driven healthcare technology company revolutionizing diagnostics through advanced platforms for laboratory operations, clinical decision support, data management and security and research analytics. The company operates a genetic laboratory infrastructure specializing in proprietary next-generation genetic testing, delivering precision insights that power data-informed care across medical, government, wellness and research sectors.
Together, the company offers a comprehensive ecosystem in digital wellness health uniting artificial intelligence, clinical diagnostics, genomics and personalized supplement recommendations into a single, scalable solution for both consumer and enterprise markets. The financial terms were not disclosed.
According to data captured in the LevinPro HC database, this transaction marks the 84th Laboratories, MRI and Dialysis transaction of the year, and the 46th in the diagnostic specialty. Throughout all of 2024, there were 122 Laboratories, MRI and Dialysis transactions, 64 of them diagnostic deals.
